🇺🇸 SRPT — Sarepta Therapeutics, Inc.

Salud Mantener
← Volver

Precio actual

17,82 USD

Máx. histórico

178,74

2145 días

Split 1:6 del 12/07/2012

Caída desde máximo

-90,03%

Rango 52 semanas

14,68 – 24,68

Variación hoy

+1,42%

Cierre anterior

17,57

Rango de hoy

17,52 – 18,77

Volumen hoy

2.596.193

Peor caída histórica

-98,17%

09/02/2000 → 18/12/2008

Recuperado en 3568 días

Volatilidad anualizada ⓘ

95,43%

Información
Nombre completo
Sarepta Therapeutics, Inc.
Divisa
USD
Mercado
NasdaqGS
Sector
Salud
Industria
Biotechnology
Empleados
835
PER ⓘ
—
Dividend yield
0,00% (puede no estar actualizado)
Precio objetivo analistas
21,64 USD (puede no estar actualizado)
Primera cotización
04/06/1997
Precio actualizado
hace 19 horas
Sobre la empresa

Sarepta Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, siRNA platform, gene therapy, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 for the treatment of Duchenne in patients who have a confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of Duchenne in patients who have a confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of Duchenne in patients who have a confirmed mutation of the dystrophin gene that is amenable to exon 45 skipping; and ELEVIDYS, an AAV-based gene therapy, which is contraindicated in patients with any deletion in exon 8 and/or exon 9 in the Duchenne gene. The company also develops SRP-9003, a gene therapy program for the treatment of LGMD2E; SRP-1001 to selectively target and knockdown DUX4 using RNAi in Phase 1/2a clinical trials; and SRP-1003 for reduction of expression of the DMPK gene in Phase 1/2a clinical trials. It has collaboration and license agreements with F. Hoffman-La Roche Ltd; Arrowhead Pharmaceuticals, Inc.; University of Western Australia; Nationwide Children's Hospital; Hansa Biopharma; and Duke University. The company was incorporated in 1980 and is headquartered in Cambridge, Massachusetts.

Splits Registrados en el histórico de precios
Fecha Ratio
12/07/2012 1:6
Rentabilidad mensual
Evolución
Histórico día a día
Fecha Apertura Máximo Mínimo Cierre Variación Volatilidad día Volumen
24/05/2010 8,10 8,34 7,68 8,34 +3,73% 8,15% 86.983
21/05/2010 7,98 8,40 7,68 8,04 +2,29% 9,02% 152.950
20/05/2010 8,40 8,40 7,56 7,86 -7,09% 10,00% 265.700
19/05/2010 8,52 8,64 8,28 8,46 -1,40% 4,23% 149.533
18/05/2010 8,58 8,94 8,46 8,58 +1,42% 5,59% 396.850
17/05/2010 8,40 8,58 8,16 8,46 +1,44% 5,00% 142.383
14/05/2010 8,28 8,52 7,92 8,34 +0,00% 7,25% 193.100
13/05/2010 8,10 8,40 7,92 8,34 +4,51% 5,93% 246.383
12/05/2010 7,68 7,98 7,38 7,98 +3,91% 7,81% 238.950
11/05/2010 7,26 7,68 7,02 7,68 +2,40% 9,09% 195.117
10/05/2010 7,26 7,56 6,96 7,50 +8,70% 8,26% 195.317
07/05/2010 7,20 7,50 6,66 6,90 -4,96% 11,67% 207.800
06/05/2010 7,74 7,92 6,96 7,26 -6,92% 12,40% 261.733
05/05/2010 7,44 7,92 7,20 7,80 +4,84% 9,68% 285.383
04/05/2010 7,68 7,86 7,38 7,44 -4,62% 6,25% 185.417
03/05/2010 7,98 7,98 7,44 7,80 -1,52% 6,77% 102.650
30/04/2010 7,80 8,04 7,68 7,92 +0,76% 4,62% 210.233
29/04/2010 7,68 7,92 7,44 7,86 +3,15% 6,25% 201.217
28/04/2010 8,10 8,10 7,38 7,62 -2,31% 8,89% 280.283
27/04/2010 8,10 8,34 7,68 7,80 -3,70% 8,15% 226.850
26/04/2010 8,28 8,64 7,98 8,10 -2,17% 7,97% 342.433
23/04/2010 7,56 8,34 7,50 8,28 +8,66% 11,11% 392.383
22/04/2010 7,26 7,62 7,14 7,62 +4,10% 6,61% 188.683
21/04/2010 7,44 7,50 7,26 7,32 -1,61% 3,23% 141.633
20/04/2010 7,20 7,44 7,20 7,44 +3,33% 3,33% 73.183
19/04/2010 7,26 7,38 7,20 7,20 -1,64% 2,48% 257.167
16/04/2010 7,20 7,44 7,20 7,32 -0,81% 3,33% 152.783
15/04/2010 7,32 7,50 7,26 7,38 +0,82% 3,28% 100.217
14/04/2010 7,50 7,74 7,26 7,32 -0,81% 6,40% 264.567
13/04/2010 7,38 7,50 7,20 7,38 +0,00% 4,07% 95.833